New Drug Tirzepatide Shows Promise in Treating Sleep Apnea and Obesity

Clinical trials reveal significant improvements in sleep quality and cardiovascular health, challenging existing treatment methods.

Tirzepatide significantly reduces the number of sleep interruptions in patients with obstructive sleep apnea (OSA).
The drug also aids in weight loss and improves cardiovascular health, offering a multifaceted treatment approach.
Phase III trials included 469 participants across nine countries, showing promising results over a 52-week period.
The study suggests that tirzepatide could be an alternative to CPAP machines, which require consistent use.
Shares of companies producing traditional sleep apnea treatments dropped following the trial results.